Skip to main content
Erschienen in: Die Diabetologie 3/2022

05.04.2022 | Typ-2-Diabetes | DDG Praxisempfehlungen

Nephropathie bei Diabetes

verfasst von: Dr. Ludwig Merker, Bernd-Walter Bautsch, Thomas Ebert, Martina Guthoff, Berend Isermann

Erschienen in: Die Diabetologie | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Auszug

Auf der Webseite der Deutschen Diabetes Gesellschaft (https://​www.​deutsche-diabetes-gesellschaft.​de/​behandlung/​leitlinien) befinden sich alle PDF zum kostenlosen Download. …
Literatur
1.
Zurück zum Zitat Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98(4S):1–115 Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98(4S):1–115
2.
Zurück zum Zitat Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group (2021) KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99:1–87CrossRef Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group (2021) KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99:1–87CrossRef
3.
Zurück zum Zitat Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383:2219–2229CrossRef Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383:2219–2229CrossRef
5.
Zurück zum Zitat Mogensen CE (1982) Introduction: diabetes mellitus and the kidney. Kidney Int 21:673–675CrossRef Mogensen CE (1982) Introduction: diabetes mellitus and the kidney. Kidney Int 21:673–675CrossRef
6.
Zurück zum Zitat KDIGO (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150CrossRef KDIGO (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150CrossRef
7.
Zurück zum Zitat Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104CrossRef Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104CrossRef
8.
Zurück zum Zitat Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63:221–228CrossRef Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63:221–228CrossRef
9.
Zurück zum Zitat Landgraf R, Aberle J, Birkenfeld AL et al (2019) Therapie des Typ-2-Diabetes. Diabetol Stoffwechs 14:167–187CrossRef Landgraf R, Aberle J, Birkenfeld AL et al (2019) Therapie des Typ-2-Diabetes. Diabetol Stoffwechs 14:167–187CrossRef
10.
Zurück zum Zitat Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 41:111–188CrossRef Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 41:111–188CrossRef
11.
Zurück zum Zitat Kristensen SL, Rørth R, Jhund PS et al (2019) Cardiovascular, mortality, and kidney outcomes with GLP‑1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7:776–785CrossRef Kristensen SL, Rørth R, Jhund PS et al (2019) Cardiovascular, mortality, and kidney outcomes with GLP‑1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7:776–785CrossRef
12.
Zurück zum Zitat Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39CrossRef Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39CrossRef
13.
Zurück zum Zitat Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306CrossRef Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306CrossRef
Metadaten
Titel
Nephropathie bei Diabetes
verfasst von
Dr. Ludwig Merker
Bernd-Walter Bautsch
Thomas Ebert
Martina Guthoff
Berend Isermann
Publikationsdatum
05.04.2022
Verlag
Springer Medizin
Erschienen in
Die Diabetologie / Ausgabe 3/2022
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI
https://doi.org/10.1007/s11428-022-00886-5

Weitere Artikel der Ausgabe 3/2022

Die Diabetologie 3/2022 Zur Ausgabe

DDG Praxisempfehlungen

Diabetische Neuropathie

DDG Praxisempfehlungen

Diabetisches Fußsyndrom

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.